Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $21.79 is 141.04% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 22.02||$ 27.82|
|Low:||$ 21.44||$ 9.04|
Company Description (as filed with the SEC)
We are a late-stage biopharmaceutical company that is committed to rewriting treatment for people with cancer and other serious diseases through the discovery, development, and commercialization of novel epigenetic medicines. By focusing on the genetic drivers of disease, our science seeks to match targeted medicines with the patients who need them. We are developing our lead product candidate, tazemetostat, an oral, first-in-class, selective small molecule inhibitor of the EZH2 histone methyltransferase, or HMT, for the treatment of a broad range of cancer types in multiple treatment settings, and developing our novel G9a program, EZM8266, for the treatment of sickle cell disease, or SCD. We have taken a "pipeline in a product" approach to developing tazemetostat with a broad clinical development program through company-sponsored studies and collaborations. ... More ...
Nasdaq Official Price
Jan. 29, 2020